Search

Your search keyword '"Vargova, Veronika"' showing total 34 results

Search Constraints

Start Over You searched for: Author "Vargova, Veronika" Remove constraint Author: "Vargova, Veronika"
34 results on '"Vargova, Veronika"'

Search Results

5. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial

11. Additional file 2 of High-dose saccharin supplementation does not induce gut microbiota changes or glucose intolerance in healthy humans and mice

12. Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee

13. Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: Analysis by the Pharmachild Safety Adjudication Committee

14. High-dose saccharin supplementation does not induce gut microbiota changes or glucose intolerance in healthy humans and mice

16. High dose saccharin supplementation does not induce gut microbiota dysbiosis or glucose intolerance in healthy humans and mice

17. Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis.

18. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study

19. Development of New Juvenile Arthritis Disease Activity Score Cut-Offs for Oligoarthritis and RF-Negative Polyarthritis from a Large Multinational Cohort of Children with Juvenile Idiopathic Arthritis

20. Development of New Juvenile Arthritis Disease Activity Score Cut-Offs for Oligoarthritis and RF-Negative Polyarthritis from a Large Multinational Cohort of Children with Juvenile Idiopathic Arthritis

22. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial

23. A52: The Impact of Adalimumab on Growth in Patients With Juvenile Idiopathic Arthritis

24. Additional file 4 of Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee

25. Additional file 4 of Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee

27. Additional file 3 of Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee

28. The Addition of One or More Biologics to Methotrexate in Children with Juvenile Idiopathic Arthritis Increases the Incidence of Infections and Other Adverse Events

29. Additional file 1 of Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee

30. Additional file 2 of Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee

31. Additional file 1 of Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee

32. Additional file 2 of Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee

33. Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee

34. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study

Catalog

Books, media, physical & digital resources